Tuesday, August 28, 2018 7:39:09 PM
the special PP private interest want to see efficacy at 50 patients lets say if the trial goes in 2 cohorts.
Also those guys didn't want warrants under their own holdings.. so .50 is a minimum now..
the most significant data is 6 months in predicting 12.. and is the retreatment interval for Phase 2.
Therefore 'maximum' confidence can be ascertained at an 'intermediate-endpoints'
which is what Dr.Gottlieb speaks about when discussing small companies with trials with outsized results that are over and above expectations regardign 'Cures Act'
The same NIH institution that funded Dr.McFarland 3.2/5 years Dr.Collins is Director who presents with Dr.Gottlieb.. so we forsure have attention cross border in top medical spots.
This trial is designed for out maximum-success potential.. IMO after watching the AGM
The path seems clear to me with this logic. (but hey) i didn't make money with pot or crypto so IMHO...
Hopefully we can get a nice 2018 run
GRO3 INFORMATION
Love stocks that have; Revenues, No Toxic Debts & Innovative
project ambitions.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM